Sensus Healthcare (NASDAQ:SRTS) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen downgraded shares of Sensus Healthcare (NASDAQ:SRTS) from a hold rating to a sell rating in a report released on Saturday morning.

Several other equities analysts have also recently weighed in on SRTS. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sensus Healthcare in a research note on Thursday, January 22nd. Zacks Research raised shares of Sensus Healthcare from a “strong sell” rating to a “hold” rating in a research report on Wednesday, October 22nd. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $8.00.

Sensus Healthcare Stock Down 17.0%

Shares of NASDAQ:SRTS opened at $3.86 on Friday. The company’s fifty day moving average is $4.46 and its two-hundred day moving average is $3.92. The company has a market cap of $63.40 million, a P/E ratio of -8.21 and a beta of 1.21. Sensus Healthcare has a 12-month low of $3.03 and a 12-month high of $5.92.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings results on Thursday, February 12th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.10). The business had revenue of $4.94 million for the quarter, compared to analysts’ expectations of $8.35 million. Sensus Healthcare had a negative net margin of 28.09% and a negative return on equity of 14.82%. Equities research analysts anticipate that Sensus Healthcare will post 0.32 earnings per share for the current year.

Insider Activity

In other Sensus Healthcare news, CEO Joseph C. Sardano acquired 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 18th. The shares were purchased at an average price of $4.03 per share, with a total value of $100,750.00. Following the completion of the transaction, the chief executive officer owned 1,200,293 shares in the company, valued at $4,837,180.79. The trade was a 2.13% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Eric Sachetta bought 7,000 shares of Sensus Healthcare stock in a transaction on Friday, November 21st. The stock was acquired at an average price of $3.93 per share, with a total value of $27,510.00. Following the completion of the purchase, the director directly owned 140,113 shares of the company’s stock, valued at approximately $550,644.09. The trade was a 5.26% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have bought 33,000 shares of company stock valued at $132,060. 8.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Sensus Healthcare

Hedge funds have recently bought and sold shares of the business. Opes Wealth Management LLC bought a new position in Sensus Healthcare during the third quarter valued at about $50,000. Vise Technologies Inc. acquired a new position in shares of Sensus Healthcare during the 2nd quarter valued at about $52,000. Jane Street Group LLC bought a new position in shares of Sensus Healthcare in the 4th quarter valued at approximately $79,000. Mindset Wealth Management LLC lifted its holdings in Sensus Healthcare by 28.1% in the 3rd quarter. Mindset Wealth Management LLC now owns 50,100 shares of the company’s stock worth $157,000 after purchasing an additional 11,000 shares during the last quarter. Finally, Ingalls & Snyder LLC bought a new stake in Sensus Healthcare during the fourth quarter worth approximately $219,000. 25.30% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Sensus Healthcare

Here are the key news stories impacting Sensus Healthcare this week:

• Positive Sentiment: Publication of dedicated CPT codes for superficial radiation therapy (SRT) to treat non‑melanoma skin cancer — a potential boost to reimbursement and broader adoption that could improve unit economics over time. Business Wire: Q4 2025 Results & CPT Codes
• Positive Sentiment: Management is explicitly targeting profitability in 2026 by expanding reimbursement, diversifying the customer base and driving adoption — a constructive strategic path if execution and reimbursement traction continue. Seeking Alpha: Profitability Target 2026
• Neutral Sentiment: Earnings call transcripts and highlights show management discussing reimbursement progress and operating initiatives; no material upside guidance was issued to offset the quarter’s miss. Useful for detail but did not reverse market reaction. MSN: Q4 2025 Earnings Call Transcript
• Negative Sentiment: Q4 results materially missed expectations: EPS of ($0.19) vs. consensus (~($0.09)) and revenue $4.94M vs. ~$8.35M consensus; the company reported a quarterly net loss and negative margins — a near‑term catalyst for selling pressure. Company Press Release: Q4 2025 Results
• Negative Sentiment: Longer‑term shareholder returns have been weak (article notes a ~36% loss over three years), underscoring investor sensitivity to execution and growth consistency. Yahoo Finance: Shareholder Returns

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.